EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp

Bank of New York Mellon Corp boosted its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 22.2% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 204,260 shares of the company’s stock after acquiring an additional 37,054 shares during the period. Bank of New York Mellon Corp owned about 0.30% of EyePoint Pharmaceuticals worth $1,522,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in EyePoint Pharmaceuticals by 40.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 14,472 shares of the company’s stock worth $108,000 after acquiring an additional 4,179 shares during the period. Intech Investment Management LLC acquired a new position in EyePoint Pharmaceuticals during the third quarter worth $136,000. Cyndeo Wealth Partners LLC raised its position in EyePoint Pharmaceuticals by 35.5% during the fourth quarter. Cyndeo Wealth Partners LLC now owns 16,990 shares of the company’s stock worth $127,000 after acquiring an additional 4,450 shares during the period. Deltec Asset Management LLC acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth $151,000. Finally, GSA Capital Partners LLP raised its position in EyePoint Pharmaceuticals by 129.6% during the third quarter. GSA Capital Partners LLP now owns 32,979 shares of the company’s stock worth $264,000 after acquiring an additional 18,616 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

EyePoint Pharmaceuticals Trading Up 2.5 %

Shares of EYPT opened at $6.25 on Friday. EyePoint Pharmaceuticals, Inc. has a 12-month low of $5.54 and a 12-month high of $23.65. The firm has a 50-day moving average price of $6.93 and a 200 day moving average price of $8.30. The firm has a market capitalization of $429.56 million, a P/E ratio of -3.13 and a beta of 1.41.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to analysts’ expectations of $11.02 million. Equities research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on EYPT shares. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a “sell” rating in a research report on Friday, March 14th. Chardan Capital reiterated a “buy” rating and issued a $33.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 target price on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $26.63.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.